Article

FDA Approves FluMist's Use in Young Children

The US Food and Drug Administration has approved the use of the nasal influenza vaccine FluMist in children ages 2?5.

The US Food and Drug Administration has approved the use of the nasal influenza vaccine FluMist in children ages 2–5. Approval for the vaccine was previously limited to healthy children 5 years of age and older and adults up to age 49.

Before this approval, there were only two vaccines licensed in the US for children under the age of 5. One of the vaccines, Fluzone, is indicated for people over 6 months of age, while Fluvirin, the other vaccine, is for use in children age 4 and older.

FDA release

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related Videos
Behind the Headlines, Episode 23: Patent Cliff Deals, Tariff Pressures, and the In Vivo Cell Therapy Bet
© 2025 MJH Life Sciences

All rights reserved.